Заказать звонок
/ Пресса о ботоксе

Литература

Интернет-магазин товаров от потливости hh-store.ru.
Специализированные товары для любой области. Доставка в любой регион РФ, другую страну.
ВАША ПЕРСОНАЛЬНАЯ СКИДКА 5%

Литература.

1. Grusser O-J. Die ersten systematischen Berschreibungen und tierexperimentellen Untersuchungen des Botulismus. Sudhoffs Archiv 1986; 2: 167–187.

2. van Ermengen E. Uber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus. Z. Hyg. Infektionskrankh 1897; 26: 1–56.

3. Leuchs J. Beitrage zur Kenntnis des Toxins und Antitoxins des Bacillus botulinus. Z. Hyg. Infektionskrankh 1910; 65: 55–84.

4. Schantz EJ. Historical Perspective. In: Jankovic J., Hallett M., eds. Therapy with Botulinum Toxin. New York, Basel, Hong Kong: Marcel Dekker, Inc. 1994: XXII-XXVI.

5. Schantz EJ., Johnson EA., Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol. Med. 1997; 40: 317–337.

6. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87: 1044–1049.

7. Scott AB. Foreword. In: Jankovic J., Hallett M., eds. Therapy with Botulium Toxin. New York, Basel, Hong Kong: Marcel Dekker Inc. 1994: VII-IX.

8. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am. Ophthalmol. Soc. 1981; 79: 734–770.

9. Fahn S., Marsden CD., Calne DB. Clarification and investigation of dystonia. In: Marsden CD., Fahn S., eds. Movement Disorders. London: Butterworths 1987: 323–361.

10. Bhatia KP., Marsden CD. The behavioural and motor consequences of local lesions of the basal ganglia in man. Brain 1994; 117: 859–876.

11. Grandas Perez FJ., Elston JS., Quinn NP., Marsden CD. Blepharospasm: a review of 264 patients. J. Neurol. Neurosurg. Psychiatry 1988; 51: 767–772.

12. Blitzer A., Brin MF., Greene PE., Fahn S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann. Otol. Rhinol. Laryngol. 1989; 98: 93–97.

13. Therapeutics and Technology Assessement Subcommittee of the American Academy of Neurology. Assessment: The clinical usefulness of Botulinum Toxin-A in treating neurologic disorders. Neurology 1990; 40: 1332–1336.

14. Lowenstein DH., Aminoff MJ. The clinical course of spasmodic torticollis. Neurology 1998; 38: 530–532.

15. Tsui JK., Eisen A., Mak E., Carruthers J., Scott A., Calne DB. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can. J. Neurol. Sci. 1985; 12: 314–316.

16. Meares R. Natural history of spasmodic torticollis, and effect of surgery. Lancet 1971; 11: 149–151.

17. Sheehy MP., Marsden CD. Writer’s cramp — a focal dystonia. Brain 1982; 105: 461–480.

18. Cohen LG., Hallett M., Geller BD., Hochberg F. Treatment of focal dystonias of the hand with botulinum toxin injections. J. Neurosurg. Psychiatry 1989; 52: 355–363.

19. Cole R., Hallet M., Cohen LG. Double-blind trial of botulinum toxin for treatment of focal hand dystonia. Mov. Disord. 1995; 10: 466–471.

20. Jankovic J., Schwartz KS. Use of botulinum toxin in the treatment of hand dystonia. J. Hand Surg. [Am] 1993; 18A: 883–887.

21. Karp BI., Cole RA., Cohen LG., Grill S., Lou JS., Hallett M. Long-term botulinum toxin treatment of focal hand dystonia. Neurology 1994; 44: 70–76.

22. Quirk JA., Sheean GL., Marsden CD., Lees AJ. Treatment of nonoccupational limb and trunk dystonia with botulinum toxin. Mov. Disord 1996; 11: 377–383.

23. Rivest J., Lees AJ., Marsden CD. Writer’s cramp: treatment with botulinum toxin injections. Mov. Disord. 1991; 6: 55–59.

24. Wissel J., Kabus C., Wenzel R., Klepsch S., Schwarz U., Nebe A., Schelosky L., Scholz U., Poewe W. Botulinum toxin in writer’s cramp: objective response evaluation in 31 patients. J. Neurol. Neurosurg. Psychiatry 1996; 61: 172–175.

25. Blitzer A., Brin MF. Laryngeal dystonia: a series with botulinum toxin therapy. Ann. Otol. Rhinol Laryngol 1991; 100: 85–89.

26. Grillone GA., Blitzer A., Brin MF., Annino DJ., Saint-Hilaire M-H. Treatment of adductor laryngeal breathing dystonia with botulinum toxin type A. Laryngoscope 1994; 104: 30–32.

27. Davidson BJ., Ludlow CL. Long-term effects of botulinum toxin injections in spasmodic dysphonia. Ann. Otol. Rhinol. Laryngol. 1996; 105: 33–42.

28. Wissel J., Poewe W. Electromyography for indentification of Dystonic Muscles. In: Moore P., ed. Botulinum Toxin Treatment. Oxford., Berlin., Wien., Paris: 1995: 54–70.

29. Barker FG., Jannetta PJ., Bissonette DJ., Shields PT., Larkins MV., Jho Hd. Microvascular decompression for hemifacial spasm. J. Neurosurg. 1995; 82: 201–210.

30. Elston JS. Botulinum toxin treatment of hemifacial spasm. J. Neurol. Neurosurg. Psychiatry 1986; 49: 827–829.

31. Savino PJ., Sergott RC., Bosley TM., Schatz NJ. Hemifacial spasm treated with botulinum A toxin injection. Arch. Ophthal. 1985; 103: 1305–1306.

32. Tolosa E., Marti MJ., Kulisevsky J. Botulinum toxin injection therapy for hemifacial spasm. Adv. Neurol. 1988; 49: 479–491.

33. Geller BD., Hallett M., Ravits J. Botulinum toxin therapy in hemifacial spasm: clinical and electrophysiologic studies. Muscle Nerve. 1989; 12: 716–722.

34. Jitpimolmard S., Tiamkao S., Laopaiboon M. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J. Neurol. Nerosurg. Psychiatry 1998; 64: 751–757.

35. Young RR. Spasticity: a review [see comments]. Neurology. 1994; 44: S12-S20.

36. Lance JW. Symposion synopsis. In: Feldman RG., Young RR., Koella WP., eds. Spasticity: disorders motor control. Chicago: Yearbook Medical 1980: 485–494.

37. Bhakta BB., Cozens JA., Bamford JM., Chamberlain MA. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J. Neurol. Neurosurg. Psychiatry. 1996; 61: 30–35.

38. Brin MF. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity Study Group. Muscle Nerve Suppl. 1997; 6: S208-S220.

39. Girlanda P., Quartarone A., Sinicropi S., Nicolosi C., Roberto ML., Picciolo G., Macaione V., Battaglia F., Ruggeri M., Messina C. Botulinum toxin in upper limb spasticity: study of reciprocal inhibition between forearm muscles. Neuroreport 1997; 8: 3039–3044.

40. Hesse S., Lucke D., Malezic M., Bertelt C., Friedrich H., Gregoric M., Mauritz KH. Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients. J. Neurol. Neurosurg. Psychiatry 1994; 57: 1321–1324.

41. Snow BJ., Tsui JK., Bhatt MH., Varelas M., Hashimoto SA., Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study [see comments]. Ann. Neurol. 1990; 28: 512–515.

42. Watanade Y., Bakheit AM., McLellan DL. A study of the effectiveness of botulinum toxin type A (Dysport) in the management of muscle spasticity. Disabil. Rehabil. 1998; 20: 62–65.

43. Pahwa R., Busenbark K., Swanson-Hyland EF., et al. Botulinum toxin treatment of essential head tremor. Neurology. 1995; 45: 822–824.

44. Lees AJ., Tolosa E. Tics. In: Jankovic J., Tolosa E., eds. Parkinson’s Disease and Movement Disorders. Baltimore, Hong Kong, London, Munich, Philadelphia, Sydney, Tokio: Williams and Wilkins 1993: 329–335.

45. Jankovic J. Botulinum toxin in the treatment of dystonic tics. Mov. Disord. 1994; 9: 347–349.

46. Wheeler AH. Botulinum toxin A, adjunctive therapy for refractory headaches associatedwith pericranial muscle tension. Headache 1998; 38: 468–471.

47. Zwart JA., Bovin G., Sand T., Sjaastad O. Tension headache: botulinum toxin paralysis of temporal muscles. Headache 1994; 34: 458–462.

48. Morre HA., Keizer SB., van Os JJ. Treatment of chronic tennis elbow with botulinum toxin. Lancet 1997; 349: 1746.

49. Varney SM., Demetroulakos JL., Fletcher MH. Palatal myoclonus: treatment with Clostridium botulinum toxin injections. Otolaryngol. Head. Neck. Surg. 1996; 114: 317–320.

50. Brin MF., Stewart C., Blitzer A., Diamond B. Laryngeal botulinum toxin injections for disabling stuttering in adults. Neurology 1994; 44: 2262–2266.

51. Brin MF., Vapnek JM. Treatment of vaginismus with botulinum toxin injections. Lancet 1997; 349: 252–253.

52. Hallan RI., Williams NS., Melling J., Waldron DJ., Womack NR., Morrison JF. Treatment of anismus in intractable constipation with botulinum A toxin. Lancet 1988; 2 (8613): 714–717.

53. Helveston EM., Pogrebniak AE. Treatment of acquired nystagmus with botulinum A toxin. Am. J. Ophthalmol. 1988; 106: 584–586.

54. Hallett M. One man’s poison — clinical applications of botulinum toxin [editorial; comment]. N. Engl. J. Med. 1999; 341: 118–120.

55. Hambleton P, Moore AP. Botulinum Neurotoxins: Origin, structure, molecular actions and antibodies. In: Moore P., ed. Botulinum Toxin Treatment. Oxford, Berlin, Wien, Victoria, Paris, Cambridge: Blackwell Science Ltd. 1995: 16–33.

56. Poewe W., Wissel J. Experience with botulinum toxin in cervical dystonia. In: Jankovic J., Hallett M., eds. Therapy with Botulinum toxin. New York, Basel, Hong Kong: Marcel Dekker 1994: 267–278.

57. Tsui JK., Eisen A., Stoessl AJ., Calne DB. A double blind study of botulinum toxin in spasmodic torticollis. Lancet 1986; ii: 245–247.

58. Gelb DJ., Lowenstein DH., Aminoff MJ. Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis [see comments]. Neurology 1989; 39: 80–84.

59. Gelb DJ., Yoshimura DM., Olney RK., Lowenstein DH., Aminoff MJ. Change in pattern of muscle activity following botulinum toxin injections for torticollis. Ann. Neurol. 1991; 29: 370–376.

60. Perlmutter JS., Tempel LW., Burde R. Double-blind, placebo-controlled, crossover trial of botulinum-A toxin for torticollis. Neurology 1989; 39: 352.

61. Blackei JD., Lees AJ. Botulinum toxin treatment in spasmodic torticollis. J. Neurol. Neurosurg. Psychiatry. 1990; 53: 640–643.

62. Green P., Kang U., Fahn S., Brin M., Moskowitz C., Flaster E. Double-bind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990; 40: 1213–1218.

63. Lorentz IT., Subramaniam SS., Yiannikas C. Treatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients. Mov. Disord. 1991; 6: 145–150.

64. Ceballos-Baumann AO., Konstanzer A., Dengler R., Conrad B. Lokale Injektionen von Botulinum-Toxin A bei cervical Dystonie: Verlaufsbeobachtungen an 45 Patienten. Akt. Neurol. 1990; 17: 139–145.

65. Stell R., Thompson PD., Marsden CD. Botulinum toxin in spasmodic torticollis. J. Neurol. Neurosurg. Psychiatry 1988; 51: 920–923.

66. Jankovic J., Schwartz K., Donovan DT. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J. Neurol. 1998; 50: 593–597.

67. Tsui JK., Eisen A., Calne DB. Botulinum toxin in spasmodic torticollis. Adv. Neurol. 1988; 50: 593–597.

68. Jankovic J., Schwartz K. Botulinum toxin injections for cervical dystonia. Neurology 1990; 40: 277–280.

69. Lees AJ., Turjanski N., Rivest J.,Whurr R., Lorch M., Brookes G. Treatment of cervical dystonia hand spasm and laryngeal dystonia with botulinum toxin. J. Neurol. 1992; 239: 1–4.

70. Brin MF., Fahn S., Moskowitz C., Freidman A., Shale HM., Greene PE., Blitzer A., List T., Lange D., Lovelace RE. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov. Disord. 1987; 2: 237–254.

71. D’Costa DF., Abbott RJ. Low dose botulinum toxin in spasmodic torticollis. J. Royal. Soc. Med. 1991; 84: 650–651.

72. Payami H., Bernard S., Larsen K., Kaye J., Nutt J. Genetic anticipation in Parkinson’s disease. Neurology 1995; 45: 135–138.

73. Poewe W., Deuschl G., Nebe A., Feifel E., Wissel J., Benecke R., Kessler KR., Ceballos-Baumann AO., Ohly A., Oertel W., Kunig G. What is the optimal dose of botulinum toxin A treatment of cervical dystonia? Results of double-blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J. Neurol. Neurosurg. Psychiatry 1998; 64: 13–17.

74. Wissel, J., Schelosky, L., Ebersbach, G., and Poewe, W. A retrospective study of dose-response and dose-side effect relation in botulinum toxin treatment of cervical dystonia. Movement Disorders 1992; 7 (suppl. 1): 136.

75. Dressler D., Benecke R., Conrad B. [Botulinum toxin in therapy of craniocervical dystonia]. Nervenarzt 1989; 60: 386–393.

76. Frueh BR., Felt DP., Wojno TH., Musch DC. Treatment of blepharospasm with botulinum toxin. A preliminary report. Arch. Ophthalmol. 1984; 102: 1464–1468.

77. Elston JS., Russell RW. Effect of treatment with botulinum toxin on neurogenic blepharospasm. Br. Med. J. (Clin. Res. Ed.) 1985; 290: 1857–1859.

78. Frueh BR., Musch DC. Treatment of facial spasm with botulinum toxin. An interim report. Ophthalmology 1986; 93: 917–923.

79. Mauriello JA., Jr. Blepharospasm, Meige syndrome, and hemifacial spasm: treatment with botulinum toxin. Neurology 1985; 35: 1499–1500.

80. Scott AB., Kennedy RA., Stubbs HA. Botulinum A toxin injection as a treatment for blepharospasm. Arch. Ophthalmol. 1985; 103: 347–350.

81. Shorr N., Seiff SR., Kopelman J. The use of botulinum toxin in blepharospasm. Am. J. Ophtalmol. 1985; 99: 542–546.

82. Tsoy EA., Buckley EG., Dutton JJ. Treatment of blepharospasm with botulinum toxin. Am. J. Ophthalmol. 1985; 99: 176–179.

83. Biglan AW., May M., Walden PG. Treatment of facial spasm with oculinum (Clostridium botulinum toxin): a preliminary report. Am. J. Otol. 1986; 7: 65–70.

84. Cohen DA., Savino PJ., Stern MB., Hurtig HI. Botulinum injection therapy for blepharospasm: a review and report of 75 patients. Clin. Neuropharmacol 1986; 9: 415–429.

85. Dutton JJ., Buckley EG. Botulinum toxin in the management of blepharospasm. Arch. Neurol. 1986; 43: 380–382.

86. Berlin AJ., Cassen JH., De Nelsky G., Hanson MR., Sweeney PJ. Benign essential blepharospasm treated with botulinum toxin. Cleve. Clin. J. Med. 1987; 54: 421–426.

87. Elston JS. Long-term results of treatment of idiopathic blepharospasm with botulinum toxin injections. Br. J. Ophthalmol. 1987; 71: 664–668.

88. Engstrom PF., Arnoult JB., Mazow Ml., Prager TC., Wilkins RB., Byrd WA., Hofmann RJ. Effectiveness of botulinum toxin therapy for essential blepharospasm. Ophthalmology 1987; 94: 971–975.

89. Jankovic J., Orman J. Botulinum-A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study. Neurology 1987; 37: 616–623.

90. Roggenkamper P. [Blepharospasm treatment with botulinum toxin (follow-up)] [Blepharospasmus-Behandlung mit Botulinus-Toxin (Verlaufsbeobachtungen).]. Klin. Monatsbl. Augenheilkd 1986; 189: 283–285.

91. Shaari CM., Sanders I. Assessment of the biological activity of Botulinum Toxin. In: Jankovic J., Hallet M., eds. Therapy with Botulinum Toxin. New York, Basel, Hong Kong: Marcel Dekker, Inc. 1994: 159–172.

92. Carruthers A., Carruthers J. The treatment of glabellar furrows with botulinum A exotoxin. J. Dermatol. Surg. Oncol. 1990; 16: 83.

93. Scott AB. Clostridial toxins as therapeutic agents. In: Simpson LL., ed. Botulinum Neurotoxin and Tetanus Toxin. New York: Academic Press, 1989: 399–412.

94. Carruthers A., Carruthers J. Botulinum toxin use for glabellar wrinkles. Presented at the annual meeting of the American Society for Dermatologic Surgery., Orlando Florida., March 1991, 13–17.

95. Carruthers A., Carruthers J. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J. Dermatol. Surg. Oncol. 1992; 18: 17–21.

96. Carruthers A., Carruthers J. History of the cosmetic use of botulinum A exotoxin. Dermatol. Surg. 1998; 24: 1168–1170.

97. Blitzer A., Brin MF., Keen MF., et al. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch. Otolaryngol. Head Neck Surg 1993; 119: 1018–1022.

98. Lowe NJ., Maxwell A., Harper H. Botulinum A exotoxin for glabellar folds: a double-blind, placebo-controlled study with an electromyographic injections technique. J. Am. Acad. Dermatol. 1996; 35: 569–572.

99. Hankins CL., Strimling R., Rogers GS. Botulinum A toxin for glabellar wrinkles: dose and response. Dermatol. Surg. 1998; 24: 1181–1183.

100. Carruthers J., Carruthers A. The adjunctive usage of botulinum toxin. Dermatol. Surg. 1998; 24: 1244–1247.

101. Shelley WB., Talanin NY., Shelley ED. Botulinum toxin therapy for palmar hyperhidrosis. J. Am. Acad. Dermatol. 1998; 38: 27–29.

102. Glogau RG. Botulinum A neurotoxin for axillary hyperhidrosis: Botox®. Dermatol Surg. 1998; 24: 817–819.

103. Heckmann M., Ceballos-Baumann A., Schaller M., Plewig G. Botulinum Toxin A in der Dermatologie. Hautarzt 1998; 49: 87–90.

104. Klein AW., Carruthers A. Why devote an issue to Botulinum Toxin. Editorial, special issue on denervation techniques for facial rejuvenation. Dermatol. Surg. 1998; 24: 1167.

105. Hambleton P. Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. J. Neurol. 1992; 239: 16–20.

106. Das Gupta BR., Sugiyama H. Biochemistry and pharmacology of botulinum and tetanus neurotoxins. In: Bernheimer AW., ed. Perspectives in Toxicology. New York: Wiley 1977: 87–119.

107. Sloop RR., Cole BA., Escutin RO. Human response to botulinum toxin injection: type B compared with type A. Neurology 1997; 49: 189–194.

108. Mezaki T., Kaji R., Kohara N., Fujii H., Katayama M., Shimizu T., Kimura J., Brin MF. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study. Neurology 1995; 45: 506–508.

109. Eleopra R., Tugnoli V., Rossetto O., Montecucco C., De Grandis D. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci Lett 1997; 224: 91–94.

110. Black JD., Dolly JO. Interaction of 125I-labelled Botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantification of distinct membrane acceptors for types A and B on motor nerves. J. Cell. Biol. 1986; 103: 521–534.

111. Black JD., Dolly JO. Interaction of 125I-labelled botulinum neurotoxin with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by acceptormediated endocytosis. J. Cell. Biol. 1986; 103: 535–544.

112. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve. Suppl. 1997; 6: S146-S168.

113. Hesse S., Jahnke MT., Luecke D., Mauritz KH. Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the of lower limb spasticipy in hemiparetic patients. Neurosci Lett 1995; 201: 37–40.

114. de Paiva A., Meunier FA., Molgo J., Aoki KR., Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc. Natl. Acad. Sci. USA 1999; 96: 3200–3205.

115. Holds JB., Alderson K., Fogg SG., Anderson RL. Motor nerve sprouting in human orbicularis muscle after botulinum A injection. Invest. Ophthalmol. Vis. Sci. 1990; 31: 964–967.

116. Borodic GE., Ferante R. Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J. Clin. Neuroopphthalmol 1992; 12: 121–127.

117. Harris CP., Alderson K., Nebeker J., Holds JB., Anderson RL. Histologic features of human orbicularis oculi treated with botulinum A toxin. Arch. Ophthalmol. 1991; 109: 393–395.

118. Borodic GE., Ferrante R., Pearce LB., Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections. Mov. Disord. 1994; 9: 31–39.

119. Borodic GE., Pearce LB., Smith K., Joseph M. Botulinum toxin for spasmodic torticollis: multiple vs. single injection points per muscle. Head Neck 1992; 14: 33–37.

120. Eleopra R., Tugnoli V., Caniatti L., De Grandis D. Botulinum toxin treatment in the facial muscle of humans: evidence of an action in untreated near muscles by peripheral local diffusion. Neurology 1996; 46: 1158–1160.

121. Marion M-H., Sheehy M., Sangla S., Soulayrol S. Dose standardization of botulinum toxin. J. Neurol. Neurosurg. Psychiatry 1995; 59: 102–103.

122. Odergren T., Hjaltason H., Kaakkola S., Solders G., Hanko J., Fehling C., Marttila RJ., Lundh H., Gerdin S., Westergren I., Richardson A., Dott C., Cohen H. A double blind, randomized, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J. Neurol. Neurosurg. Psychiatry 1998; 64: 6–12.

123. Krack P., Deuschl G., Benecke R., Ceballos-Baumann AO., Marion MH., Oertel WH., Poewe W. Dose standardization of botulinum toxin [letter]. Mov. Disord. 1998; 13: 749–751.

124. Quinn N., Hallett M. Dose standardization of botulinum toxin [letter] [published erratum appears in Lancet 1989 May 13; 1 (8646): [see comments]. Lancet 1989; 1: 964.

125. Buchman AS., Comella Cl., Stebbins GT., Weinstein SL. Determining a dose-effect curve for botulinum toxin in the sternocleidomastoid muscle in cervical dystonia. Clin. Neuropharmacol. 1994; 17: 188–195.

126. Scott AB., Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov. Disord. 1988; 3: 333–335.

127. Vita G., Girlanda P., Puglisi RM., Marabello L., Messina C. Cardiovascular-reflex-testing and single fiber electromyography in botulism. A longitudinal study. Arch. Neurol. 1987; 44: 202–206.

128. Girlanda P., Vita G., Nicolosi C., Milone S., Messina C. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J. Neurol. Neurosurg. Psychiatry 1992; 55: 844–845.

129. Lange DJ., Brin MF., Fanh S., Lovelace RE. Distant effects of locally injected botulinum toxin: incidence and course. Adv. Neurol. 1988; 50: 609–613.

130. Olney RK., Aminoff MJ., Gelb DJ., Lowenstein DH. Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 1988; 38: 1780–1783.

131. Claus D., Druschky A., Erbguth F. Botulinum toxin: influence on respiratory heart rate variation. Mov. Disord. 1995; 10: 574–579.

132. Sampaio C., Castro-Caldas A., Sales-Luis MI., Alves M., Pinto L., Apolinario P. Brachial plexopathy after Botulinum toxin administration for cervical dystonia [letter] [see comments]. J. Neurol. Neurosurg. Psychiatry 1993; 56: 220.

133. Vieregge P., Kompf D. Brachial plexopathy after botulinum toxin administration for cervical dystonia [letter; comment]. J. Neurol. Neurosurg. Psychiatry 1993; 56: 1338–1339.

134. Zuber M., Sebald M., Bathien N., De Recondo J., Rondot P. Botulinum antibodies in dystonic patient treated with type A botulinum toxin: Frequency and significance. Neurology 1993; 43: 1715–1718.

135. Tsui JK., Wong, NLM., Wong E. and Calne DB. Production of circulation of circulating antibodies to Botulinum-A toxin in patients receiving repeated injections for dystonia. Annals of Neurology 1988; 23: 181.

136. Borodic GE., Duane D., Pearce B., Johnson E. Antibodies to botulinum toxin [letter]. Neurology 1995; 45: 204.

137. Goschel H., Wohlfarth K., Frevert J., Dengler R., Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequence. Exp. Neurol. 1997; 147: 96–102.

138. Borodic G., Johnson E., Goodnough M., Schantz E. Botukinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 1996; 46: 26–29.

139. Kessler KR., Benecke R. The EBD test — a clinical test for the detection of antibodies to botulinum toxin type A. Mov. Disord 1997; 12: 95–99.

140. Dressler D. Botulinum Toxin therapy failure: cause, evaluation procedures and management strategies. Eur. J. Neurol. 1997; 4 (suppl. 2): S67-S70.

141. Greene P., Fahn S., Diamond B. Development of resistance to botulinum toxin type A patients with torticollis. Mov. Disord. 1994; 9: 213–217.

142. Chen R., Karp BI., Hallett M. Botulinum toxin type F for treatment of dystonia: long-term experience. Neurology 1998; 51: 1494–1496.

143. Greene PE., Fahn S. Response to botulinum toxin F in seronegative botulinum toxin A-resistant patients. Mov. Disord. 1996; 11: 181–184.

144. Houser MK., Sheean GL., Lees AJ. Further studies studies using higher dose of botulinum toxin type F for torticollis resistant to botulinum toxin type A.J. Neurol. Neurosurg. Psychiatry 1998; 64: 577–580.

145. Cullis PA., O’Brien CF., Truong DD., Koller M., Villegas TP., Wallace JD. Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients. Adv. Neurol. 1998; 78: 227–230.

146. Truong DD., Cullis PA., O’Brien CF., Koller M., Villegas TP., Wallace JD. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study). Mov. Disord. 1997; 12: 772–775.

147. Putz HG. Sobotta Atlas der Anatomie des Menschen, Band 1. Urban&Schwarzenberg Munchen Wien Baltimore, 19. Auflage 1999: 133–134.

148. Schiebler TH., Schmidt W. Lehrbuch der gesamten Anatomie des Menschen. Springer-Verlag Berlin Heidelberg New York. 2. Auflage 1981: 350–351.

149. Ascher B., Klap P., Marion MH., et al. La toxine botulique dans le traitement des tides fronto-glabellaires et de la region orbitaire. Ann. Chir. Plast. Esthet 1995; 40: 67–76.

150. Blitzer A., Binder WJ., Avev JE. The management of hyperfunctional facial lines with botulinum toxin: a collaborative study of 210 injection sites in 162 patients. Arch. Otolaryngol. Head Neck Surg. 1997; 123: 389–392.

151. Borodic GE., Ferrante RJ., Pearce LB., et al. Pharmacology and histology of the therapeutic application of botulinum toxin. In: Jankovic J., Hallett M (eds). Therapy with botulinum toxin. Marcel Dekker, New York, 1994: 119–157.

152. Brandt FS., Bellmann B. Cosmetic use of botulinum for the aging neck. Dermatol. Surg. 1998; 24: 1272–1274.

153. Carruthers A., Carruthers J. Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin. Dermatol Surg. 1998; 24: 1189–1194.

154. Carruthers A., Carruthers J. Cosmetic uses of botulinum toxin. In: Coleman WP III, Hanke CW., Alt. TH., Asken S (eds). Cosmetic Surgery of the Skin. Mosby St. Louis, Baltimore, 2nd edition 1997: 231–235.

155. Carruthers A., Carruthres J. Cosmetic uses of botulinum toxin. In: Klein AW (ed) Tissue Augmentation in Clinical Practice. Marcel. Dekker, New York, Basel, Hong Kong, 1st edition 1998: 207–236.

156. Carruthers A., Carruthers J. Botulinum toxin in the treatment of glabellar frown lines and other facial wrinkles. In: Jankovic J., Hallett M (eds) Therapy with botulinum toxin. Marcel Dekker, New York, Baltimore, 1994: 577–595.

157. Carruthes A., Carruthers J. The use of botulinum toxin to treat glabellar frown lines and other facial wrinkles. Cosmet Dermatol. 1994; 7: 11–15.

158. Carruthers A., Keine K., Carruthers J. Botulinum A exotoxin use in clinical dermatology. J. Am. Acad. Dermatol 1996; 34: 788–797.

159. Carruthers J., Carruthers A. BTX-A in clinical ophthalmology. Can. J. Ophthalmol 1996; 31: 389–399.

160. Carruthers J., Carruthers A. Combining botulinum toxin injection and laser resurfacing for facial rhytides. In: Coleman WP., Lawrence N (eds) Skin resurfacing. Williams&Wilkins, Baltimore 1997: 235–243.

161. Carruthers J., Carruthers A. Cosmetic uses of botulinum A exotoxin. In: Dzubow L (ed) Adv. Dermatol 1996; 12: 280–303.

162. Carruthers J., Carruthers A. The adjunctive usage of botulinum toxin. Dermatol Surg. 1998; 24: 1244–1247.

163. Carruthers J., Carruthers A. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J. Dermatol Surg. Onacol. 1992; 18: 17–21.

164. Comella C., Buchman AS., Tanner CM, et al. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyography assistance. Neurology 1992; 42: 878–882.

165. Fachinformation Botox®, Fa. Allergan.

166. Fachinformation Dysport®, Fa. Ipsen Pharma.

167. Fulton JE Jr., Gaminchi F. Sleep lines. Dermatol Surg. 1999; 25: 59–62.

168. Garcia A., Fulton E. Cosmetic denervation of the muscles of facial expression with botulinum toxin. Dermatol Surg. 1996; 22: 39–43.

169. Guyuron B., Huddleston SW. Aesthetic indications for botulinum toxin injection. Plast. Reconstr. Surg. 1994; 93: 913–918.

170. Hoefflin SM. Anatomy of the platysma and lip depressor muscles. Dermatol Surg. 1998; 24: 1225–1231.

171. Huang W., Rogachefsky AS., Foster JA. Browlift with botulinum toxin. Dermatol. Surg. 2000; 26: 55–60.

172. Huilgol SC., Carruthers A., Carruthers J. Raising eyebrows with botulinum toxin. Dermatol. Surg. 1999; 25: 373–375.

173. Jancovic J., Brin MF. Therapeutic uses of Botulinum toxin. N. Engl. J. Med. 1991: 324: 1186–1193.

174. Jancovic J., Hallett M (eds). Therapy with Botulinum Toxin. Marcel Dekker, New York: 1994.

175. Keen M., Blitzer A., Aviv J., et al. Botulinum toxin A for hyperkinetic facial lines: results of a double-blind, placebo-controlled study. Plast. Reconstr. Surg. 1994; 94: 94–99.

176. Keen M., Kopelman JE., Aviv JE., et al. Botulinum toxin: a novel method to remove periorbital wrinkles. Facial Plast. Surg. 1994; 10; 141–146.

177. Klein AW., Mantell A. Electromyographic guidance in injecting botulinum toxin. Dermatol Surg. 1998; 24: 1184–1186.

178. Klein AW., Wexler P., Carruthers A., Carruthers J. Treatment of facial furrows and rhytids. Analysis and treatment of the aging face. Dermatol Clin. 1997; 15: 595–607.

179. Klein AW. Cosmetic therapy with botulinum toxin: anecdotal memoirs. Dermatol Surg. 1996; 22: 757–759.

180. Klein AW. Dilution and Storage of Botulinum Toxin. Dermatol Surg. 1998; 24: 1179–1180.

181. Kubiena G., Sommer B. (Hrsg) Therapiehandbuch Akupunktur. Urban und Fischer, Munchen, Jena. 2. Auflage 1999.

182. Low MJ., Wieder JM. Botulinum toxin for hyperkinetic facial lines: a placebo-controlled study. Cosmet. Dermatol. 1995; 8: 46–47.

183. Lowe NJ. Botulinum Toxin Type A for Facial Rejuvenation. United States and United Kingdom Perspectives. Dermatol Surg. 1998; 24: 1216–1218.

184. Matarasso SL. Complications of botulinum A exotoxin for hyperfunctional lines. Dermatol Surg. 1998; 24: 1249–1254.

185. O’Brien CF. Injection techniques for botulinum toxin using electromyography and electrical stimulation. Muscle Nerve 1997, Suppl. 6: 176–180.

186. Sommer B., Sattler G. Botulinum A exotoxin, headache and acupuncture. Presentation at the 20th Congress of the International Society for Dermatologic Surgery, Athens, Greece, Sept. 1999.

187. Sommer B., Sattler G. Liposuktion. In: Sommer B., Sattler G., Hanke CW (Hrsg) Tumeszenz-Lokalanasthesie. Springer Verlag Berlin, Heidelberg, 1998: 63–82.

Ссылки по теме:

Закрыть